Does insulin therapy activate the anti-aging gene Sirtuin 1 that is critical for the prevention of insulin iresistance?
The anti-aging gene Sirtuin 1 is important to the prevention of accelerated aging and diabetes. Sirtuin 1 activators are critical to the treatment of diabetes, cardiovascular disease and Alzheimer’s disease. Sirtuin 1 inhibitors cause insulin resistance and reduce plasma Sirtuin 1 levels. Insulin therapy is critical to the treatment of diabetes and plasma Sirtuin 1 levels need to be measured with relevance to the treatment and prevention of insulin resistance.
RELEVANT REFERENCES:
1. Anti-Aging Genes Improve Appetite Regulation and Reverse Cell Senescence and Apoptosis in Global Populations. Advances in Aging Research, 2016, 5, 9-26.
2. Single Gene Inactivation with Implications to Diabetes and Multiple Organ Dysfunction Syndrome. J Clin Epigenet. 2017; Vol. 3 No. 3:24.
3. Sirtuin 1, a Diagnostic Protein Marker and its Relevance to Chronic Disease and Therapeutic Drug Interventions”. EC Pharmacology and Toxicology 6.4 (2018): 209-215.
4. Nutrition Therapy Regulates Caffeine Metabolism with Relevance to NAFLD and Induction of Type 3 Diabetes. J Diabetes Metab Disord. 2017; 4: 019.
5. Insulin Therapy and Autoimmune Disease with Relevance to Nonalcoholic Fatty Liver Disease. Non Alcoholic Fatty Liver Disease. An Update. IntechOpen. 2018
Arvind
Sirtuins, originally identified as Sir2 in yeast, have become pivotal in ageing and age-related disease research due to their protective functions against tissue and organ degeneration in older individuals. These proteins represent valuable targets for interventions designed to address various age-associated pathologies. During the past 15 years, considerable efforts have focused on developing isoform-specific small molecule modulators, furthering comprehension of sirtuins’ enzymatic mechanisms and roles in disease processes. Importantly, effective SIRT1 activators and SIRT2 inhibitors have been discovered through drug development initiatives, with several compounds progressing to early-stage clinical trials, demonstrating both safety and efficacy.
Despite these advances, challenges remain—most notably, the absence of standardised disease models for evaluating sirtuin therapeutics. This shortcoming has led to variability in research outcomes and complicated validation across studies. Additionally, the translation of these molecules into clinically viable therapies involves addressing issues such as potential adverse effects, molecular stability, and target specificity. Nevertheless, research on sirtuin modulators continues to advance the field of drug discovery and holds considerable promise for treating both common and rare diseases for which medical needs remain unmet.
Fede996